BlackRock Inc. Takes Position in Immix Biopharma, Inc. $IMMX

Key Points

• BlackRock acquired 2.99 million Immix Biopharma shares in the second quarter, valued at approximately $30.8 million and representing a 5.5% stake. Institutional and hedge-fund investors collectively own 11.26% of IMMX.
• IMMX shares opened at $14.01, near their 52-week high of $15.10, while the company reported a quarterly loss of $0.18 per share—slightly worse than analysts’ $0.17 estimate.
• Analyst sentiment remains broadly positive: eight analysts rate the stock a Buy and one rates it Sell, producing a “Moderate Buy” consensus and an average price target of $21.29.

BlackRock Inc. acquired a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,989,972 shares of the company's stock, valued at approximately $30,827,000. BlackRock Inc. owned approximately 5.50% of Immix Biopharma as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in IMMX. Deutsche Bank AG purchased a new position in Immix Biopharma in the 2nd quarter valued at $421,000. Bank of New York Mellon Corp acquired a new stake in shares of Immix Biopharma in the 2nd quarter worth $2,430,000. State of Wyoming acquired a new stake in shares of Immix Biopharma in the 2nd quarter worth $140,000. GSA Capital Partners LLP purchased a new stake in shares of Immix Biopharma in the second quarter valued at about $205,000. Finally, Everhart Financial Group Inc. purchased a new stake in Immix Biopharma in the 2nd quarter valued at about $103,000. 11.26% of the stock is owned by hedge funds and other institutional investors.

Immix Biopharma Trading Down 0.1%

Shares of Immix Biopharma stock opened at $14.01 on Wednesday. Immix Biopharma, Inc. has a 1 year low of $1.94 and a 1 year high of $15.10. The company's fifty day simple moving average is $10.79 and its 200-day simple moving average is $9.67. The company has a market cap of $1.00 billion, a price-to-earnings ratio of -15.92 and a beta of 0.20.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last announced its earnings results on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.01). As a group, research analysts forecast that Immix Biopharma, Inc. will post -0.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Needham & Company LLC initiated coverage on shares of Immix Biopharma in a research report on Wednesday, July 22nd. They issued a "buy" rating and a $21.00 target price on the stock. Bank of America initiated coverage on shares of Immix Biopharma in a research note on Thursday, June 18th. They set a "buy" rating and a $27.00 price target on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Immix Biopharma in a research note on Friday, July 17th. Morgan Stanley lowered their target price on shares of Immix Biopharma from $20.00 to $19.00 and set an "overweight" rating for the company in a research note on Tuesday, August 11th. Finally, Citigroup reiterated a "market outperform" rating on shares of Immix Biopharma in a research report on Friday, August 14th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $21.29.

About Immix Biopharma

Immix Biopharma NASDAQ: IMMX is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company's approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company's lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source